par Van Cutsem, Eric;Tejpar, Sabine;Vanbeckevoort, Dirk;Peeters, Marc;Humblet, Yves;Gelderblom, Hans;Vermorken, Jan B;Viret, Frederic;Glimelius, Bengt;Gallerani, Elisa;Hendlisz, Alain
;Cats, Annemieke;Moehler, Markus;Sagaert, Xavier;Vlassak, Soetkin;Schlichting, P.;Ciardiello, Fortunato
Référence Journal of clinical oncology, 30, 23, page (2861-2868)
Publication Publié, 2012-08

Référence Journal of clinical oncology, 30, 23, page (2861-2868)
Publication Publié, 2012-08
Article révisé par les pairs
Titre: |
|
Auteur: | Van Cutsem, Eric; Tejpar, Sabine; Vanbeckevoort, Dirk; Peeters, Marc; Humblet, Yves; Gelderblom, Hans; Vermorken, Jan B; Viret, Frederic; Glimelius, Bengt; Gallerani, Elisa; Hendlisz, Alain; Cats, Annemieke; Moehler, Markus; Sagaert, Xavier; Vlassak, Soetkin; Schlichting, P.; Ciardiello, Fortunato |
Informations sur la publication: | Journal of clinical oncology, 30, 23, page (2861-2868) |
Statut de publication: | Publié, 2012-08 |
Sujet CREF: | Cancérologie |
MeSH keywords: | Aged |
Antibodies, Monoclonal -- administration & dosage -- adverse effects | |
Antineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effects | |
Camptothecin -- administration & dosage -- analogs & derivatives | |
Colorectal Neoplasms -- drug therapy -- secondary | |
Dose-Response Relationship, Drug | |
Drug Eruptions -- classification -- etiology | |
Female | |
Humans | |
Male | |
Middle Aged | |
Note générale: | Clinical Trial, Phase I |
Clinical Trial, Phase II | |
Journal Article | |
Multicenter Study | |
Randomized Controlled Trial | |
Research Support, Non-U.S. Gov't | |
SCOPUS: ar.j | |
Langue: | Anglais |
Identificateurs: | urn:issn:0732-183X |
info:doi/10.1200/JCO.2011.40.9243 | |
info:pii/JCO.2011.40.9243 | |
info:scp/84865092896 | |
info:pmid/22753904 |